Date: 07 July 2014
Description: A Direct Healthcare Professional Communication (DHPC) has been approved by NPCB to inform healthcare professionals of serious skin reactions, namely Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), associated with Vectibix®.This product should be discontinued if SJS/TEN is suspected. The package inserts for Vectibix® will be updated by GlaxoSmithkline Pharmaceuticals (Malaysia) Sdn. Bhd. to reflect this new safety information. Please refer to the DHPC for further information.